Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

被引:374
作者
Husereau, Don [1 ,2 ]
Drummond, Michael [3 ]
Augustovski, Federico [4 ,5 ]
De Bekker-Grob, Esther [10 ]
Briggs, Andrew H. [6 ]
Carswell, Chris [7 ]
Caulley, Lisa [8 ]
Chaiyakunapruk, Nathorn [9 ]
Greenberg, Dan [11 ]
Loder, Elizabeth [12 ]
Mauskopf, Josephine [13 ]
Mullins, C. Daniel [14 ]
Petrou, Stavros [15 ]
Pwu, Raoh-Fang [16 ]
Staniszewska, Sophie [17 ]
机构
[1] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[2] Inst Hlth Econ, Edmonton, AB, Canada
[3] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
[4] Inst Clin Effectiveness & Hlth Policy, Hlth Technol Assessment & Hlth Econ, Buenos Aires, DF, Argentina
[5] Natl Sci & Tech Res Council Buenos Aires, Buenos Aires, DF, Argentina
[6] London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London, England
[7] Springer Nat, Auckland, New Zealand
[8] Ottawa Hosp, Ottawa, ON, Canada
[9] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA
[10] Erasmus Univ, Sch Hlth Policy & Management, Rotterdam, Netherlands
[11] Ben Gurion Univ Negev, Dept Hlth Syst Management, Beer Sheva, Israel
[12] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[13] RTI Int, Res Triangle Pk, NC USA
[14] Univ Maryland, Pharmaceut Hlth Serv Res Dept, Baltimore, MD USA
[15] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, Oxon, England
[16] Taiwan Minist Hlth & Welf, Taipei, Taiwan
[17] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England
关键词
COST-EFFECTIVENESS ANALYSIS; CLINICAL-TRIALS; GUIDELINES; RECOMMENDATIONS; IMPACT; DESIGN;
D O I
10.1016/j.jval.2021.11.1351
中图分类号
F [经济];
学科分类号
02 ;
摘要
Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 45 条
  • [31] CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials
    Junqueira, Daniela R.
    Zorzela, Liliane
    Golder, Susan
    Loke, Yoon
    Gagnier, Joel J.
    Julious, Steven A.
    Li, Tianjing
    Mayo-Wilson, Evan
    Pham, Ba
    Phillips, Rachel
    Santaguida, Pasqualina
    Scherer, Roberta W.
    Gotzsche, Peter C.
    Moher, David
    Ioannidis, John P. A.
    Vohra, Sunita
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2023, 158 : 149 - 165
  • [32] CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials
    Junqueira, Daniela R.
    Zorzela, Liliane
    Golder, Susan
    Loke, Yoon
    Gagnier, Joel J.
    Julious, Steven A.
    Li, Tianjing
    Mayo-Wilson, Evan
    Pham, Ba
    Phillips, Rachel
    Santaguida, Pasqualina
    Scherer, Roberta W.
    Gotzsche, Peter C.
    Moher, David
    Ioannidis, John P. A.
    Vohra, Sunita
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 381
  • [33] Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement
    Huria, Tania
    Palmer, Suetonia C.
    Pitama, Suzanne
    Beckert, Lutz
    Lacey, Cameron
    Ewen, Shaun
    Smith, Linda Tuhiwai
    BMC MEDICAL RESEARCH METHODOLOGY, 2019, 19 (01)
  • [34] Reporting Quality in Health Economic Evaluation Studies of Immune Checkpoint Inhibitors: A Systematic Review
    Yoshioka, Takashi
    Azuma, Shintaro
    Funada, Satoshi
    Itaya, Takahiro
    Goto, Rei
    CLINICAL DRUG INVESTIGATION, 2025, : 223 - 234
  • [35] STARE-HI - Statement on reporting of evaluation studies in Health Informatics
    Talmon, Jan
    Ammenwerth, Elske
    Brender, Jytte
    de Keizer, Nicolette
    Nykaenen, Pirkko
    Rigby, Michael
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2009, 78 (01) : 1 - 9
  • [36] Guidance on the use of complex systems models for economic evaluations of public health interventions
    Breeze, Penny R.
    Squires, Hazel
    Ennis, Kate
    Meier, Petra
    Hayes, Kate
    Lomax, Nik
    Shiell, Alan
    Kee, Frank
    de Vocht, Frank
    O'Flaherty, Martin
    Gilbert, Nigel
    Purshouse, Robin
    Robinson, Stewart
    Dodd, Peter J.
    Strong, Mark
    Paisley, Suzy
    Smith, Richard
    Briggs, Andrew
    Shahab, Lion
    Occhipinti, Jo-An
    Lawson, Kenny
    Bayley, Thomas
    Smith, Robert
    Boyd, Jennifer
    Kadirkamanathan, Visakan
    Cookson, Richard
    Hernandez-Alava, Monica
    Jackson, Christopher H.
    Karapici, Amanda
    Sassi, Franco
    Scarborough, Peter
    Siebert, Uwe
    Silverman, Eric
    Vale, Luke
    Walsh, Cathal
    Brennan, Alan
    HEALTH ECONOMICS, 2023, 32 (07) : 1603 - 1625
  • [37] STARE-HI - Statement on Reporting of Evaluation Studies in Health Informatics Explanation and Elaboration
    Brender, J.
    Talmon, J.
    de Keizer, N.
    Nykanen, P.
    Rigby, M.
    Ammenwerth, E.
    APPLIED CLINICAL INFORMATICS, 2013, 4 (03): : 331 - 358
  • [38] A scoping review of evaluation and acceptability criteria for the accuracy of cost estimates in health economic evaluations
    Fgaier, Meriem
    Zrubka, Zsombor
    28TH INTERNATIONAL CONFERENCE ON INTELLIGENT ENGINEERING SYSTEMS, INES 2024, 2024, : 89 - 94
  • [39] German recommendations on health economic evaluation - Third and updated version of the Hanover Consensus
    von der Schulenburg, J. -M. Graf
    Greiner, W.
    Jost, F.
    Klusen, N.
    Kubin, M.
    Leidl, R.
    Mittendorf, T.
    Rebscher, H.
    Schoeffski, O.
    Vauth, C.
    Volmer, T.
    Wahler, S.
    Wasem, J.
    Weber, C.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2007, 12 (05): : 285 - 290
  • [40] German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus
    von der Schulenburg, J. -Matthias Graf
    Greiner, Wolfgang
    Jost, Fred
    Klusen, Norbert
    Kubin, Maria
    Leidl, Reiner
    Mittendorf, Thomas
    Rebscher, Herbert
    Schoeffski, Oliver
    Vauth, Christoph
    Volmer, Timm
    Wahler, Steffen
    Wasem, Juergen
    Weber, Christian
    VALUE IN HEALTH, 2008, 11 (04) : 539 - 544